- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT07892027
Natalizumab for the Prevention of ICANS in Patients With Recurrent or Refractory Diffuse Large B-Cell Lymphoma or Mantle Cell Lymphoma Receiving CAR T-Cell Therapy
Phase II Trial of Natalizumab for Prevention of Immune Effector Cell Associated Neurologic Syndrome (ICANS) in Patients Treated With Chimeric Antigen Receptor T-Cell Therapy for B-Cell Hematologic Malignancies
This phase II studies how well natalizumab works in preventing immune effector cell associated neurologic syndrome (ICANS) in patients with diffuse large B-cell lymphoma (DLBCL) or mantle cell lymphoma (MCL) that has come back after a period of improvement (recurrent) or that does not respond to treatment (refractory) receiving chimeric antigen receptor (CAR) T-cell therapy. A major complication of CAR T-cell therapy is ICANS. ICANS is inflammation of the brain or nerves. ICANS currently requires high-dose corticosteroid treatment which can inhibit CAR T-cell response. Natalizumab prevents immune cells from traveling from the blood to the fluid around the brain, which is a process thought to play a major role in CAR T-cell related brain injury. Natalizumab may be safe and effective in decreasing the frequency of severe ICANS in patients with DLBCL or MCL receiving CAR T-cell therapy.
Panoramica dello studio
Stato
Condizioni
Tipo di studio
Iscrizione (Stimato)
Fase
- Fase 2
Contatti e Sedi
Contatto studio
- Nome: Tracey Churay
- Numero di telefono: 1-800-865-1125
- Email: tchuray@med.umich.edu
Luoghi di studio
-
-
Michigan
-
Ann Arbor, Michigan, Stati Uniti, 48109
- Reclutamento
- University of Michigan Rogel Cancer Center
-
Investigatore principale:
- Monalisa Ghosh
-
Contatto:
- Tracey Churay
- Numero di telefono: 800-865-1125
- Email: tchuray@med.umich.edu
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
- Patient must be ≥ 18 years of age at the time of signing informed consent (ICF)
- Patient must understand and voluntarily sign the ICF prior to conduct of any study-related assessments or procedures
- Patient must be willing to adhere to the study visit schedule and other protocol requirements
- Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2
- Patient must be eligible per institutional criteria for therapy with commercial axicabtagene ciloleucel or brexucabtagene autoleucel for treatment of relapsed or refractory diffuse large B-cell lymphoma or mantle cell lymphoma
- Per institutional protocol: Females and males of childbearing potential must be willing to abstain from heterosexual activity or to use 2 forms of effective methods of contraception from the time of informed consent until 12 months (female) or 4 months (males with female partners of reproductive potential) after the cyclophosphamide infusion. The two contraception methods can consist of two barrier methods or a barrier method plus a hormonal method. Female participants must agree to inform their male partners that they must use the methods of birth control required by the protocol. The use of intrauterine devices is excluded due to the risk of infection or bleeding
Exclusion Criteria:
-
Uncontrolled systemic fungal, bacterial, viral, or other infection despite appropriate antibiotics or treatment
- Patients with infections controlled on antibiotics are not excluded
-
Prior history or current infection with John Cunningham (JC) virus
-
Active hepatitis B or C (latent hepatitis B will not be excluded), or HIV. Entecavir prophylaxis can be used for latent hepatitis B. Patients' viral load must be undetectable per quantitative polymerase chain reaction (PCR) and/or nucleic acid testing at screening
-
Bilirubin: ≥ 2.0 x upper limit of normal (ULN), unless attributed to Gilbert's Syndrome or to the patient's primary malignancy
-
Aspartate aminotransferase (AST): ≥ 5 x ULN, alanine aminotransferase (ALT): ≥ 5 x ULN
-
Active concurrent autoimmune disease requiring immunosuppressive therapy
-
Active central nervous system (CNS) lymphoma
-
Active clinically relevant central nervous system disease including but not limited to:
- Seizures/epilepsy
- Stroke within the past 12 months, or unstable neurologic deficits within the past 12 months
- Cerebral edema
- Aphasia
- Severe brain injury
- Cerebellar disease
- Documented history of dementia by clinical diagnosis
- Parkinson's disease
- Psychosis
-
Pregnant or nursing females
-
History of or active progressive multifocal leukoencephalopathy (PML)
-
Prior history or active herpes encephalitis or meningitis infection
-
Current treatment with any other agents for prophylaxis of CRS or ICANS, including investigational agents. Use of antiseizure medications does not exclude patients
-
History of prior exposure to natalizumab due to risk of neutralizing antibody formation
-
History of hypersensitivity reaction to natalizumab or the formulation excipients
-
Consider adding: History of, or a concurrent, clinically significant illness, medical condition or laboratory abnormality that, in the investigator's opinion, could affect the conduct of the study
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Terapia di supporto
- Assegnazione: N / A
- Modello interventistico: Assegnazione di gruppo singolo
- Mascheramento: Nessuno (etichetta aperta)
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
|---|---|
|
Sperimentale: Supportive care (SOC conditioning & CAR-T, natalizumab)
Patients receive SOC conditioning therapy consisting of fludarabine IV and cyclophosphamide IV on days -4 and -3. Patients then receive natalizumab IV over 1 hour on day -1, followed by SOC CAR T-cell therapy with axicabtagene ciloleucel or brexucabtagene autoleucel on day 0. Patients also undergo PET/CT and blood sample collection throughout the study. |
Given IV
Altri nomi:
Undergo collection of blood
Altri nomi:
Undergo PET/CT
Altri nomi:
Given IV
Altri nomi:
Undergo PET/CT
Altri nomi:
Given axicabtagene ciloleucel
Altri nomi:
Given brexucabtagene autoleucel
Altri nomi:
Given IV
Altri nomi:
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Occurrence of chimeric antigen receptor therapy (CAR-T)-associated neurotoxicity (immune effector cell associated neurotoxicity syndrome [ICANS])
Lasso di tempo: Up to CAR-T day +28
|
Any grade per American Society for Transplantation and Cellular Therapy Cytokine Release Syndrome (ASTCT) criteria. Will be considered binary and the rate will be defined as number of patients without ICANS of any grade divided by the number of evaluable patients. These rates will be reported along with the 95% exact binomial confidence interval. |
Up to CAR-T day +28
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Occurrence of severe CAR-T-associated neurotoxicity (ICANS of grade 3 or greater)
Lasso di tempo: Up to CAR-T day +28
|
Defined by ASTCT consensus criteria. Will be considered binary and the rate will be defined as number of patients with severe ICANS divided by the number of evaluable patients. These rates will be reported along with the 95% exact binomial confidence interval. |
Up to CAR-T day +28
|
|
Occurrence of severe cytokine release syndrome (cytokine release syndrome [CRS] of grade 3 or greater)
Lasso di tempo: Up to CAR-T day +28
|
Defined by ASTCT consensus criteria. Will be considered binary, and the rate will be defined as number of patients with severe CRS divided by the number of evaluable patients. These rates will be reported along with the 95% exact binomial confidence interval. |
Up to CAR-T day +28
|
|
Occurrence of adverse events related to natalizumab
Lasso di tempo: Up to CAR-T day +28
|
Treatment emergent adverse events will be tabulated, and the rate will be defined as number of patients with treatment emergent adverse events divided by the number of evaluable patients. These rates will be reported along with the 95% exact binomial confidence interval. |
Up to CAR-T day +28
|
|
Occurrence of complete response or partial response
Lasso di tempo: At CAR-T day +60
|
Assessed per Lugano classification on day +60 positron emission tomography/computed tomography. Will be defined as number of patients with treatment emergent adverse events divided by the number of evaluable patients. These rates will be reported along with the 95% exact binomial confidence interval. |
At CAR-T day +60
|
|
Occurrence of serious adverse events related to natalizumab
Lasso di tempo: Up to CAR-T day +28
|
Treatment emergent serious adverse events will be tabulated, and the rate will be defined as number of patients with treatment emergent adverse events divided by the number of evaluable patients. These rates will be reported along with the 95% exact binomial confidence interval. |
Up to CAR-T day +28
|
Collaboratori e investigatori
Investigatori
- Investigatore principale: Monalisa Ghosh, University of Michigan Rogel Cancer Center
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Completamento primario (Stimato)
Completamento dello studio (Stimato)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Termini MeSH pertinenti aggiuntivi
- Neoplasie
- Malattie del sistema immunitario
- Neoplasie per tipo istologico
- Malattie linfatiche
- Malattie linfoproliferative
- Disturbi immunoproliferativi
- Linfoma non Hodgkin
- Linfoma, cellule B
- Linfoma
- Malattie emiche e linfatiche
- Linfoma, a grandi cellule B, diffuso
- Linfoma, cellule del mantello
- Aminoacidi, peptidi e proteine
- Proteine
- Prodotti chimici organici
- Tecniche investigative
- Tecniche di laboratorio clinico
- Tecniche e procedure diagnostiche
- Diagnosi
- Idrocarburi
- Anticorpi, monoclonali, umanizzati
- Anticorpi, monoclonali
- Anticorpi
- Immunoglobuline
- Immunoproteine
- Proteine del sangue
- Globuline sieriche
- Globuline
- Tecniche di chimica, analitiche
- Analisi dello spettro
- Senape di fosforamide
- Composti di senape di azoto
- Composti di senape
- Idrocarburi, alogenati
- Fosforamidi
- Composti organofosfori
- Natalizumab
- Ciclofosfamide
- Gestione dei campioni
- Spettroscopia di risonanza magnetica
- fludarabina
- Autoleucel di Brexucabtagene
- Axicabtagene Ciloleucel
- monoclonal antibody AN100226
Altri numeri di identificazione dello studio
- UMCC 2026.011
- NCI-2026-05450 (Identificatore di registro: CTRP (Clinical Trial Reporting Program))
- HUM00289351 (Altro identificatore: University of Michigan Rogel Cancer Center)
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
prodotto fabbricato ed esportato dagli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .